RAPID COMMUNICATION CD34+ Peripheral Blood Progenitors as a Target for Genetic Correction of the Two Flavocytochrome bSs8 Defective Forms of Chronic Granulomatous Disease
نویسندگان
چکیده
Chronic granulomatous disease (CGD) can result from any of four single gene defects involving components of the superoxide (0;')-generating phagocyte NADPH oxidase (phox). The phox transmembrane flavocytochrome bsss is composed of two peptides, gpS1Ph" and ~ 2 2 ~ " " . Mutations of gp9lW" cause X-linked CGD, whereas mutations of p22pho" cause one of the three autosomal recessive forms of CGD. We used the Maloney leukemia virus-based MFG retrovirus vector to produce replication defective retroviruses encoding gpSlPh"" or ~ 2 2 ~ ~ " " . To maximize viral titer MFG retroviruses do not contain internal promoter or resistance elements. Epstein-Barr virus transformed B-lymphocyte cell lines (EBV-B) derived from normal individuals contain phox components and produce 0;'. whereas those derived from CGD patients show the CGD defect. Transduction of gp9lPhox or p22Ph""-deficient CGD EBV-B lines resulted in correction of 0," production from a barely detectable
منابع مشابه
Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer.
Chronic granulomatous disease (CGD) can result from any of four single gene defects involving the components of the superoxide (O-2) generating phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. We show that transduction of peripheral blood CD34+ hematopoietic progenitors from a p67phox deficient CGD patient with replication defective amphotropic retrovirus encoding p67phox ...
متن کاملGenetic Correction of p67 Deficient Chronic Granulomatous Disease Using Peripheral Blood Progenitor Cells as a Target for Retrovirus Mediated Gene Transfer
Chronic granulomatous disease (CGD) can result from any from transduced CD34 progenitors from the p67 CGD patient were oxidase positive with the average level of corof four single gene defects involving the components of the superoxide (O2 ) generating phagocyte nicotinamide aderection per granulocyte of 85% of that seen with granulocytes in similar cultures of CD34 progenitors from normal nine...
متن کاملGENE THERAPY Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/ 2-microglobulin / repopulating mobilized human peripheral blood CD34 cells
In previous studies amphotropic MFGSgp91phox (murine onco-retrovirus vector) was used in a clinical trial of X-linked chronic granulomatous disease (X-CGD) gene therapy to achieve transient correction of oxidase activity in 0.1% of neutrophils. We later showed that transduced CD34 peripheral blood stem cells (CD34 PBSCs) from this trial transplanted into nonobese diabetic/severe combined immuno...
متن کاملGENE THERAPY Third-generation, self-inactivating gp91phox lentivector corrects the oxidase defect in NOD/SCID mouse–repopulating peripheral blood–mobilized CD34 cells from patients with X-linked chronic granulomatous disease
HIV-1–derived lentivectors are promising for gene transfer into hematopoietic stem cells but require preclinical in vivo evaluation relevant to specific human diseases. Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice accept human hematopoietic stem cell grafts, providing a unique opportunity for in vivo evaluation of therapies targeting human hematopoietic diseases. We demonst...
متن کاملThird-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
HIV-1-derived lentivectors are promising for gene transfer into hematopoietic stem cells but require preclinical in vivo evaluation relevant to specific human diseases. Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice accept human hematopoietic stem cell grafts, providing a unique opportunity for in vivo evaluation of therapies targeting human hematopoietic diseases. We demonst...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2000